AbbVie Inc
I · AI-analyse
In het kort
AbbVie researches, develops, and sells prescription medicines across multiple therapeutic areas. Their biggest focus is immunology drugs (like Skyrizi and Rinvoq) that treat autoimmune diseases, along with cancer treatments (Imbruvica, Venclexta), neuroscience medications (Vraylar, Botox, migraine drugs), and aesthetics products (facial injectables and skincare) [Yahoo Finance]. The company also sells eye care products and treatments for digestive conditions.
AbbVie is a large pharmaceutical company headquartered in Illinois that develops and sells medicines for serious diseases including autoimmune conditions, cancer, neurological disorders, and eye diseases [Yahoo Finance]. The company spun off from Abbott Laboratories in 2013 and now employs 57,000 people worldwide, generating $61.2 billion in annual revenue [Yahoo Finance]. AbbVie is successfully transitioning away from its former blockbuster drug Humira by growing newer products like Skyrizi, Rinvoq, and neuroscience treatments [Yahoo Finance].
AbbVie is financially healthy with strong cash generation, though it carries moderate debt and trades at an unusually high valuation [Yahoo Finance].
Sentinellis-score
7.4/10
Financially healthy
Marktkapitalisatie
$377.7B
Omzet (12 maanden)
$61.2B
II · Recent nieuws
Wat de koers bewoog
6 stories · ranked by relevance
- macro2026-05-19
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
Zacks
- macro2026-05-18
Kernicterus Market Research and Forecast Report 2026-2036 Featuring Pfizer, F.Hoffmann La Roche,. Merck, AbbVie, AsteraZeneca, Abbott Laboratories, Sanofi, GlaxoSmithKline, Grifols
Yahoo Finance
- macro2026-05-19
Polymyositis Market Research Report 2026-2036: Competitive Landscape is Dominated by Major Players Such As Teva Pharmaceuticals, Gilead Sciences, Roche, AbbVie, and Pfizer
Yahoo Finance
- macro2026-05-19
2 Reasons to Like ABBV and 1 to Stay Skeptical
Yahoo Finance
- macro2026-05-18
Here's How Neuroscience Drugs Boost AbbVie's Q1 Sales Growth
Yahoo Finance
- macro2026-05-18
Cannabis Pharmaceuticals Business Research Report 2026: An $111.1 Billion Market by 2032 from $4.7 Billion in 2025 Featuring AbbVie, Aphria, Aurora Cannabis, Bausch Health, and Canopy Growth
Yahoo Finance
Premium · gratis met elk account
AbbVie generates about half its revenue from immunology treatments, creating significant concentration risk if this single therapeutic area faces competitive pressure or regulatory challenges [Yahoo Finance]
Risico's
4
Kansen
6
Waarschuwingssignalen
2
Leiding
10
Nog 21 bevindingen in het volledige rapport — gratis met elk account.
Ontgrendel de volledige analyse van AbbVie Inc
Maak een gratis account voor het volledige AI-rapport met bronvermelding in de tekst.
- 4 risico's, 6 kansen en 2 waarschuwingssignalen — elk met zijn bron
- Meer dan 100 financiële cijfers met grafieken en vergelijkingen
- Volledige nieuwssamenvattingen met bronlinks
- Directie en beloning
- PDF-export voor offline
III · Vergelijkbare bedrijven
Misschien ook interessant
Same sector · Healthcare or comparable health
Op je volglijst zetten?